News and Press

Recent Press Releases

CAMBRIDGE AND BOSTON, MA – December 19, 2018 – Pandion Therapeutics, a biotechnology platform company developing therapeutics to achieve localized immunomodulation to treat autoimmune and inflammatory disease, today announced it has received an investment from the JDRF T1D Fund. This financing will enable the company to launch a type 1 diabetes (T1D)-focused program leveraging its innovative technology platform...

CAMBRIDGE, Mass. – September 11, 2018 – ImmusanT, Inc., a clinical stage company that is leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to translate and deliver first-in-class peptide-based immune therapies to people living with autoimmune diseases, today announced that it has received an investment from the JDRF T1D Fund, a venture philanthropy fund...

MONTREAL (CANADA) – July 25, 2018 – Proceeds will support the development of novel generation cannabinoid receptor type 1 (CB1) inverse agonists for the treatment of several metabolic diseases including Prader-Willi Syndrome (PWS) and type 1 diabetes (T1D).
Today Inversago Pharma Inc. (“Inversago”) announced that it has secured a $7 million series A financing to pursue...

Milan – July 24, 2018 – Enthera S.r.l. is an innovative start-up founded in 2016 by Prof. PaoloFiorina, Dr. Francesca D’Addio and by BiovelocITA. Enthera is dedicated to the research and developmentof innovative approaches to treat type 1 diabetes and related gastrointestinal complications. The seedexpansion, led by Sofinnova Partners, a leading European...

About the JDRF T1D Fund

Our aim is to create a new investment market aimed at delivering solutions to those living with or at risk of developing T1D. Launched in December 2016, the T1D Fund is a combination of venture capital and philanthropy focused solely on T1D. It’s the first scale, mission-driven venture philanthropy fund focused on commercial investments in companies developing life-saving T1D products. The portfolio consists of therapeutics, devices, vaccines, and diagnostics. We already have made several investments and the list will only continue to grow.